TNF blockers may increase the risk of malignancy in children
Thursday, July 29, 2010 - 15:56
in Health & Medicine
The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab and their report is published in the August issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
Read the whole article on Physorg
More from Physorg
Related
- TNF blockers may increase the risk of malignancy in childrenThu, 29 Jul 2010, 16:58:30 EDT
- Etanercept helps restore normal growth in children with juvenile arthritisWed, 3 Nov 2010, 10:35:07 EDT
- Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patientsThu, 29 Oct 2009, 1:23:53 EDT
- 3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritisFri, 12 Jun 2009, 14:31:31 EDT
- Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapiesThu, 12 Jun 2008, 10:36:26 EDT